Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...

Investing.com - テレヘルス企業Hims & Hers Health (NYSE: HIMS )の株価は、製薬大手ノボ・ノルディスク (NYSE: NVO )が減量薬販売に関する同社との提携を終了すると発表した後、32%急落した。

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the company's CEO ...

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 10 Stocks Leave Wall Street Stunned. Hims & Hers extended its rally for ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...

ヒムズ＆ハーズ45.95（-18.27 -28.45%） 肥満薬の調剤版を販売する遠隔医療プラットフォームのヒムズ＆ハーズ・ヘルスが大幅安。デンマークのノボ・ノルディスクが同社との提携を終了したと発表したことが嫌気されている。